The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Open accessThe DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1R, a core member of the GPCR family, is widely present on the surfaces of various cells in the human body.1,2”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Chooi, Y. C., Ding, C., & Magkos, F. (2019) · Metabolism · doi:10.1016/j.metabol.2018.09.005 · Cited by 2,737
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Obesity as a Major Risk Factor for Cancer
De Pergola, G., & Silvestris, F. (2013) · Journal of Obesity · doi:10.1155/2013/291546 · Cited by 959
The Burden of Mortality Attributable to Diabetes
Roglic, G., Unwin, N., Bennett, P. H., Mathers, C., Tuomilehto, J., Nag, S., Connolly, V., & King, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2130 · Cited by 816
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Wolin, K. Y., Carson, K., & Colditz, G. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0285 · Cited by 778
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
Pati, S., Irfan, W., Jameel, A., Ahmed, S., & Shahid, R. K. (2023) · Cancers · doi:10.3390/cancers15020485 · Cited by 677
Colberg (2010) · doi:10.2337/dc10-1548 · Cited by 656
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Obesity and cancer risk: evidence, mechanisms, and recommendations
Vucenik, I., & Stains, J. P. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06750.x · Cited by 571
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Current views on type 2 diabetes
Lin, Y., & Sun, Z. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0260 · Cited by 457
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Zinman, B., Bhosekar, V., Busch, R., Holst, I., Ludvik, B., Thielke, D., Thrasher, J., Woo, V., & Philis-Tsimikas, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30066-x · Cited by 376
Kadowaki, T., Isendahl, J., Khalid, U., Lee, S. Y., Nishida, T., Ogawa, W., Tobe, K., Yamauchi, T., & Lim, S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00008-0 · Cited by 330
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
GLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
Obesity, Diabetes, and Increased Cancer Progression
Kim, D.-S., & Scherer, P. E. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0077 · Cited by 302
Lingvay, I., Catarig, A.-M., Frias, J. P., Kumar, H., Lausvig, N. L., le Roux, C. W., Thielke, D., Viljoen, A., & McCrimmon, R. J. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30311-0 · Cited by 298
Obesity, Type 2 Diabetes, and Cancer Risk
Scully, T., Ettela, A., LeRoith, D., & Gallagher, E. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615375 · Cited by 256
Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2019)
Harreiter, J., & Roden, M. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1450-4 · Cited by 253
Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma
Derr, R. L., Ye, X., Islas, M. U., Desideri, S., Saudek, C. D., & Grossman, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1098 · Cited by 225
Tong, G., Peng, T., Chen, Y., Sha, L., Dai, H., Xiang, Y., Zou, Z., He, H., & Wang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901559 · Cited by 218
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s008 · Cited by 215
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
Klil-Drori, A. J., Azoulay, L., & Pollak, M. N. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.120 · Cited by 210
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
The Prevention and Treatment of Obesity
Wirth, A., Wabitsch, M., & Hauner, H. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0705 · Cited by 167
Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015
Islami, F., Goding Sauer, A., Gapstur, S. M., & Jemal, A. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5639 · Cited by 153
Wang, L., Wang, W., Kaelber, D. C., Xu, R., & Berger, N. A. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5573 · Cited by 150
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
del Olmo-Garcia, M. I., & Merino-Torres, J. F. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4020492 · Cited by 138
Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 136
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Koehler, J. A., Baggio, L. L., Yusta, B., Longuet, C., Rowland, K. J., Cao, X., Holland, D., Brubaker, P. L., & Drucker, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.005 · Cited by 133
Samec, M., Líšková, A., Koklesová, L., Samuel, S. M., Zhai, K., Buhrmann, C., Varghese, E., Abotaleb, M., Qaradakhi, T., Zulli, A., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00217-y · Cited by 133
Self-citationKaku, K., Yamada, Y., Watada, H., Abiko, A., Nishida, T., Zacho, J., & Kiyosue, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13218 · Cited by 132
Rahn, S., Zimmermann, V., Viol, F., Knaack, H., Stemmer, K., Peters, L., Lenk, L., Ungefroren, H., Saur, D., Schäfer, H., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.004 · Cited by 131
Koehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 128
Seino, Y., Terauchi, Y., Osonoi, T., Yabe, D., Abe, N., Nishida, T., Zacho, J., & Kaneko, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13082 · Cited by 127
GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation
Carlessi, R., Chen, Y., Rowlands, J., Cruzat, V. F., Keane, K. N., Egan, L., Mamotte, C., Stokes, R., Gunton, J. E., Bittencourt, P. I. H. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02838-2 · Cited by 122
Ligumsky, H., Wolf, I., Israeli, S., Haimsohn, M., Ferber, S., Karasik, A., Kaufman, B., & Rubinek, T. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1585-0 · Cited by 121
Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)
Latif, W. A., Lambrinos, K. J., & Rodríguez, R. (2021) · StatPearls · Cited by 119
Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors
López-Suárez, A. (2018) · Metabolism · doi:10.1016/j.metabol.2018.10.013 · Cited by 115
Ji, L., Dong, X., Li, Y., Li, Y., Lim, S., Liu, M., Ning, Z., Rasmussen, S., Skjøth, T. V., Yuan, G., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14232 · Cited by 113
Pérez‐Rodrigo, C. (2013) · PubMed · doi:10.3305/nh.2013.28.sup5.6915 · Cited by 111
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Semaglutide: First Global Approval
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0871-0 · Cited by 104
Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules
Verbeek, H. H. G., de Groot, J. W. B., Sluiter, W. J., Kobold, A. C. M., van den Heuvel, E. R., Plukker, J. T., & Links, T. P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010159.pub2 · Cited by 96
Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
Brockmueller, A., Sameri, S., Líšková, A., Zhai, K., Varghese, E., Samuel, S. M., Büsselberg, D., Kubatka, P., & Shakibaei, M. (2021) · Cancers · doi:10.3390/cancers13020188 · Cited by 91
Self-citationZhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Iwaya, C., Nomiyama, T., Komatsu, S., Kawanami, T., Tsutsumi, Y., Hamaguchi, Y., Horikawa, T., Yoshinaga, Y., Yamashita, S., Tanaka, T., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00461 · Cited by 87
Wong, C., Lee, M. H., Yaow, C. Y. L., Chin, Y. H., Goh, X. L., Ng, C. H., Lim, A. Y. L., Muthiah, M. D., & Khoo, C. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609110 · Cited by 86
Kellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14765 · Cited by 86
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Chen, J., Yin, D., & Dou, K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01875-8 · Cited by 84
Glucose addiction in cancer therapy: advances and drawbacks
Granja, S., Pinheiro, C. M., Reis, R. M., Martinho, O., & Baltazar, F. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666150602145145 · Cited by 80
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
Detka, J., & Głombik, K. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00274-8 · Cited by 79
Lamari, Y., Boissard, C., Moukhtar, M. S., Jullienne, A., Rosselin, G., & Garel, J.-M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00895-2 · Cited by 73
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73
Buhrmann, C., Shayan, P., Brockmueller, A., & Shakibaei, M. (2020) · Molecules · doi:10.3390/molecules25184292 · Cited by 73
Self-citationActions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Adult-onset autoimmune diabetes
Buzzetti, R., Maddaloni, E., Gaglia, J. L., Leslie, R. D., Wong, F. S., & Boehm, B. O. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00390-6 · Cited by 71
Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165722 · Cited by 69
Männistö, S., Kontto, J., Kataja-Tuomola, M., Albanes, D., & Virtamo, J. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510000073 · Cited by 65
Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence
Slawinski, C. G. V., Barriuso, J., Guo, H., & Renehan, A. G. (2020) · Clinical Oncology · doi:10.1016/j.clon.2020.05.004 · Cited by 63
Hausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0532-6 · Cited by 62
Bhardwaj, P., Iyengar, N. M., Zahid, H., Carter, K. M., Byun, D. J., Choi, M. H., Sun, Q., Savenkov, O., Louka, C., Liu, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade1857 · Cited by 61
Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells
He, W., Yu, S., Wang, L., He, M., Cao, X., Li, Y., & Xiao, H. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.07.032 · Cited by 58
GLP-1R Activation by Liraglutide Promotes Breast Cancer Through NOX4/ROS/VEGF Pathway
Liu, Z., Duan, X., Yuan, M., Yu, J. Y., Hu, X., Han, X., Lan, L., Liu, B., Wang, Y., & Qin, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2022.120370 · Cited by 55
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
Wang, W., Mei, A., Qian, H., Li, D., Xu, H., Chen, J., Yang, H., Min, X., Li, C., Cheng, L., et al. (2023) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s393323 · Cited by 53
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139709 · Cited by 50
Jessen, L., Smith, E. P., Ulrich-Lai, Y., Herman, J. P., Seeley, R. J., Sandoval, D., & D’Alessio, D. (2017) · Endocrinology · doi:10.1210/en.2016-1826 · Cited by 48
Hou, Y., Ernst, S. A., Heidenreich, K., & Williams, J. A. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2015 · Cited by 47
Zhao, W., Zhang, X., Zhou, Z., Sun, B., Gu, W., Liu, J., & Zhang, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8475 · Cited by 46
Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells
Zhao, H.-J., Jiang, X., Hu, L.-J., Yang, L., Deng, L.-D., Wang, Y.-P., & Ren, Z.-P. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0186 · Cited by 43
Eftekhari, S., Montazeri, H., & Tarighi, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173102 · Cited by 43
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Impact of high glucose on metastasis of colon cancer cells
Lin, C.-Y., Lee, C.-H., Huang, C., Lee, S.-T., Guo, H., & Su, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i7.2047 · Cited by 41
Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13247 · Cited by 39
Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells
Yaylalı, G. F., Dodurga, Y., Seçme, M., & Elmas, L. (2015) · Tumor Biology · doi:10.1007/s13277-015-4104-9 · Cited by 38
Broide, E., Bloch, O., Ben-Yehudah, G., Cantrell, D., Shirin, H., & Rapoport, M. J. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413497586 · Cited by 38
Skriver, C., Friis, S., Knudsen, L. B., Catarig, A., Clark, A. J., Dehlendorff, C., & Mørch, L. S. (2023) · Diabetologia · doi:10.1007/s00125-023-05972-x · Cited by 38
Clinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
Li, X.-N., Bu, H.-M., Ma, X.-H., Lu, S., Zhao, S., Cui, Y.-L., & Sun, J. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-112368 · Cited by 36
Hansen, B. B., Nuhoho, S., Ali, S. N., Dang-Tan, T., Valentine, W. J., Malkin, S. J. P., & Hunt, B. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1722678 · Cited by 36
Rowbottom, L., Stinson, J., McDonald, R. E., Emmenegger, U., Cheng, S. Y.-S., LOWE, J. M., Giotis, A., Cheon, P., Chow, R., Pasetka, M., et al. (2015) · PubMed · doi:10.3978/j.issn.2224-5820.2015.04.07 · Cited by 33
Association between diabetes, obesity, aging, and cancer: review of recent literature
Qiang, J. K., Lipscombe, L. L., & Lega, I. C. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.14 · Cited by 33
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
Lu, R., Yang, J., Wei, R., Ke, J., Tian, Q., Yu, F., Liu, J., Zhang, J., & Hong, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198938 · Cited by 30
Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D. J., Seino, Y., & Yamada, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa201 · Cited by 29
Corrigendum: Safety of Semaglutide
Smits, M. M., & van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.786732 · Cited by 29
Glucagon‐like peptide‐1 drives energy metabolism on the synaptic highway
Liu, J., & Pang, Z. P. (2016) · The FEBS Journal · doi:10.1111/febs.13785 · Cited by 28
Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen
Zhu, L., Zhou, J., Pan, Y., Lv, J., Liu, Y., Yu, S., & Zhang, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109555 · Cited by 27
Liu, X., Patel, K. P., & Zheng, H. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022542 · Cited by 21
Khajah, M. A., Khushaish, S., & Luqmani, Y. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272449 · Cited by 21
Iijima, T., Shibuya, M., Ito, Y., & Terauchi, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14000 · Cited by 21
Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00560-z · Cited by 18
GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
Feng, Z., Tong, W. K., Zhang, X., & Tang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1226778 · Cited by 13
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 12
Metformin dosage patterns in type 2 diabetes patients in a real-world setting in the United States
Mahabaleshwarkar, R., & DeSantis, A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108531 · Cited by 8
The Effect of Glucose on Rapid Cancer Cell Proliferation & Waste
Nolen, L. (2022) · Oncology Times · doi:10.1097/01.cot.0000892616.48647.47 · Cited by 2
Research works printed but not linked: 5
- Johnson, L. R., Barret, K. E., Gishan, F. K., Merchant, J. L., Said, H. M., & Wood, J. D. (2006). Physiology of the gastrointestinal tract; ; Vol. 1–2.
- Koehler, J. A., Kain, T., & Drucker, D. J. (2011). Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology, 152,. https://doi.org/10.1210/en.2011-1201 · DOI · Paper page
- Iwaya, C., Nomiyama, T., Komatsu, S., Kawanami, T., Tsutsumi, Y., Hamaguchi, Y., Horikawa, T., Yoshinaga, Y., Yamashita, S., Tanaka, T., et al. (2017). Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-ΚB activation. Endocrinology, 158, 4218–4232. https://doi.org/10.1210/EN.2017-00461 · DOI · Paper page
- Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2022). Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetology International, 13, 480–492. https://doi.org/10.1007/s13340-021-00560-z · DOI
- Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015). Combined treatment with exendin-4 and metformin attenuates prostate cancer growth. PLoS One, 10, e0139709. https://doi.org/10.1371/journal.pone.0139709 · DOI
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Münte, E., & Hartmann, P. (2025) · Biomolecules · doi:10.3390/biom15040469 · Cited by 89
Levy, S., Attia, A., Elshazli, R., Abdelmaksoud, A., Tatum, D., Aiash, H., & Toraih, E. (2024) · Cancers · doi:10.3390/cancers17010078 · Cited by 63
Ungvari, Z. I., Bartha, Á., Ungvari, A., Fekete, M., Bianchini, G., & Győrffy, B. (2025) · GeroScience · doi:10.1007/s11357-024-01494-5 · Cited by 49
Advances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
Metadata
- Authors
- Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Anatomische Anstalt (DE)
- Corresponding author
- Büsselberg, Dietrich
- ORCID
- Venue
- Cancer and Metastasis Reviews
- Published
- 2024-05-27
- Volume
- 43
- Issue
- 4
- Pages
- 1297-1314
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- PMC
- PMC11554930
- OpenAlex
- W4399046314
- Cited by
- 56
- References
- 125
- Citations by year
- 2026: 26 · 2025: 27 · 2024: 3
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer and Metastasis Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- Qatar National Research Fund (NPRP 14S-0311–210033)
- Weill Cornell Medical College in Qatar
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, type 2 diabetes, cancer, semaglutide, glucose homeostasis, beta-cell proliferation, insulin secretion, appetite regulation, cancer risk, signaling pathways
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.